Trial Profile
Use of belatacept during post depletional repopulation to facilitate tolerance in renal allograft recipients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 May 2021
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Belatacept (Primary) ; Sirolimus (Primary) ; Methylprednisolone
- Indications Renal transplant rejection
- Focus Proof of concept; Therapeutic Use
- 03 May 2021 Results investigated the repopulating T-cell kinetics in kidney transplant recipients, published in the American Journal of Transplantation.
- 21 Jan 2020 Status changed from active, no longer recruiting to completed.
- 06 Jun 2018 Long term results presented at the 2018 American Transplant Congress.